{"url_path":"/sec/ntla/8-k/2026-04-27/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1652130/0001193125-26-179401-index.html","accession_number":"0001193125-26-179401","cik":"0001652130","ticker":"NTLA","issuer_name":"Intellia Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1652130/0001193125-26-179401-index.html","primary_entity_key":"0001652130","primary_entity_name":"Intellia Therapeutics, Inc."},"word_count":177,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure.\n\nOn April 27, 2026, Intellia Therapeutics, Inc. (the “Company”) issued a press release titled “Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing” and presented topline data from the HAELO Phase 3 trial of lonvoguran ziclumeran (“lonvo-z”) for the treatment of hereditary angioedema (“HAE”) in a presentation titled “Phase 3 HAELO Clinical Trial: Topline Data for Lonvo-z.” A copy of the press release and presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.\n\nThe information under this Item 7.01, including Exhibits 99.1 and 99.2 hereto, are being furnished herewith and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing."}